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Abstract
Background: Pathogenic yersiniae inject several effector proteins (Yops) into host cells, which subverts immune functions
and enables the bacteria to survive within the host organism. YopM, whose deletion in enteropathogenic yersiniae results in
a dramatic loss of virulence, has previously been shown to form a complex with and activate the multifunctional kinases
PKN2 and RSK1 in transfected cells.
Methodology/Principal Findings: In a near physiological approach with double-affinity-tagged YopM being translocated
into the macrophage cell line J774A.1 via the natural type three secretion system of Yersinia we verified the interaction of
YopM with PKN2 and RSK1 and detected association with additional PKN and RSK isoforms. In transfected and infected cells
YopM induced sustained phosphorylation of RSK at its activation sites serine-380 and serine-221 even in the absence of
signalling from its upstream kinase ERK1/2, suggesting inhibition of dephosphorylation. ATP-depletion and in vitro assays
using purified components directly confirmed that YopM shields RSK isoforms from phosphatase activity towards serines
380 and 221.
Conclusions/Significance: Our study suggests that during Yersinia infection YopM induces sustained activation of RSK by
blocking dephosphorylation of its activatory phosphorylation sites. This may represent a novel mode of action of a bacterial
virulence factor.
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Introduction
Yersiniae are gram-negative bacteria which belong to the family
of the Enterobacteriaceae. The genus Yersinia comprises Yersinia
pestis, the causative agent of plague, and Yersinia enterocolitica and
Yersinia pseudotuberculosis, both of which cause gastrointestinal
disease. Like many other gram negative bacteria yersiniae utilize
a so called type III-secretion system (TTSS) to inject proteins into
host cells [1]. The target cells are mostly cells of the immune
system like phagocytes, macrophages, polymorphonuclear neutro-
phils, lymphocytes and dendritic cells [2,3]. The injected virulence
proteins (‘‘Yersinia outer proteins’’, Yops) subvert the immune cells,
which permits extracellular persistence and proliferation of
Yersinia. Six different Yops, YopE, YopT, YopO/YpkA, YopH,
YopP/YopJ and YopM, are translocated and attack diverse
aspects of cellular immunity which disturbs immune cell function
at different levels [4,5]. YopE, YopT and YopO/YopkA modulate
small GTP-binding proteins of the Rho-family, which take part in
the regulation of the actin cytoskeleton. YopH is a tyrosine
phosphatase and dephosphorylates focal adhesion complexes,
thereby destroying local connections between the cytoskeleton and
the plasma membrane. The activities of YopH, YopE, YopT and
YopO reorganize the actin cytoskeleton and prevent phagocytosis,
which is essential for the uptake and degradation of bacteria by
phagocytes. The effector protein YopP targets other cellular
responses and inhibits the MAP-Kinases ERK, JNK and p38 and
the activation of the transcription factor NFkappaB [6,7]. YopP
acetylates several MAP-kinase-kinases (MAPKKs) and inhibitor of
kappaB kinase beta (IKKbeta) on critical residues resulting in
impaired activation and hence disruption of the particular
signalling pathways [8,9]. This results in reduced expression of
cytokines and apoptosis in macrophages.
In contrast, the intracellular actions of YopM remained largely
obscure. Nevertheless, YopM has an important role for in vivo
virulence of yersiniae. Deletion of the yopM gene in pathogenic
yersiniae results in a dramatic loss of virulence [10]. The size of
YopM differs between different strains and serotypes ranging from
42–54 kDa due to a variable number [11] and composition [12] of
leucine-rich-repeats (LRRs) of which YopM is mostly comprised.
In crystallization experiments YopM assembled into tetramers
which formed hollow cylinders [12]. Early experiments suggested
that YopM might be secreted into the extracellular space, where it
was thought to associate with and inhibit thrombin [13].
Subsequent studies clearly showed that YopM is injected into
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target molecules [14], yet a recent study found YopM to associate
with the extracellular alpha1-antitrypsin, albeit with unknown
consequences [15]. Intracellularly, YopM seems at least partly to be
localized in the nucleus [16,17,18] and one study using microarray
analysis found the dysregulation of several genes implicated in
cellular growth and cell cycle control [19]. In contrast a second
similarly designed study did not identify genes regulated by YopM
[20]. Thus, it is currently unclear, whether YopM exerts a
transcriptional effect on single genes. One study found a YopM
dependent depletion of NK-cells during infection with pathogenic
yersiniae, but the underlying mechanism remained elusive [21]. A
more recent study by the same group gave a more complex picture
with NK cell depletion seen only in the spleen but not in the liver
and without significance during Yersinia infection [22]. Instead,
Gr1+ polymorphonuclear neutrophils were suggested to be
important for YopM mediated virulence.
First insights into the cellular actions of YopM came from a
study by McDonald et al., who co-immunoprecipitated the kinases
RSK1 and PKN2 with YopM from transfected cells [23]. YopM
bound both kinases simultaneously assembling a trimeric complex.
In this complex RSK1 and PKN2 were both shown to be activated
by the presence of YopM as demonstrated by kinase assays with
precipitated kinases. RSK1 was directly activated by YopM while
PKN2 seemed to be activated subsequently by RSK1 in the
complex. Yet, the underlying molecular mechanisms of this
activation cascade were not further analysed. Although both
kinases are involved in multiple cellular processes a direct link to a
function in the immune system is lacking so far. The RSK family is
constituted of four different isoforms (RSK1–4) which are
activated by the ERK-signalling pathway through a complex
cascade of consecutive phosphorylations of the RSK molecule.
Phosphorylation of serine 573 (amino acid numbering refers to
human RSK1 throughout) by ERK1/2 results in autophosphor-
ylation at serine 380, which creates a docking site for another
kinase, PDK1. PDK1 then phosphorylates serine 221 in the N-
terminal kinase domain which ultimately targets substrates
[24,25]. The phosphorylation of serine 359/363 by ERK1/2
and additional yet unidentified kinases is also necessary for full
activation [26]. RSK proteins have an important role in the
‘‘immediate early gene’’ transcription following stimulation of the
cell by phosphorylating transcription factors like SRF and CREB.
Other nuclear target proteins are c-fos, Nurr77, CBP, ATF4, p300
and several others. Cytosolic substrates include among others the
sodium/proton exchanger NHE1, the proapoptotic protein BAD
and the Glycogen synthetase kinase 3 (GSK3). RSK members
have been implicated in regulating cell cycle control, phagocytosis,
apoptosis and translation. A recent study also found RanBP3 to be
a substrate of RSK, which may point towards a role in
nucleocytoplasmic transport regulation [27]. Furthermore, RSK
was identified as a central regulator of cellular mobility [28,29].
The in vivo function of the individual RSK-isoforms is not well
established. Inactivating mutations in the RSK2 gene in humans
cause the Coffin-Lowry syndrome [30], yet Rsk2 knockout mice
show only very moderate phenotypes [31]. Phenotypes of other
RSK-knockout mice have not yet been published. PKN proteins
are also multifunctional proteins [32]. Three different isoforms of
PKN (PKN1-3) exist and like RSK these proteins have been found
to be involved in multiple cellular processes. PKN proteins are
regulated through their interaction with Rho-GTPases, PDK1 and
various lipids. One current model of the activation of PKN
assumes that active Rho-GTPases associate with PKN which
provides a docking site for PDK1 [33]. After binding, PDK1
phosphorylates PKN at a specific threonine in the activation loop
(T774 in PKN1 and T816 in PKN2). PKN2 participates in the
regulation of the actin cytoskeleton, cell adhesion, and cell cycle
progression [34]. Furthermore, PKN is involved in transcriptional
regulation by phosphorylating transcription factors like the
Androgenreceptor (AR), Estrogenreceptor (ER), Heat Shock
Factor 1 (HSF1) and Histone H3 [35]. Phenotypes of knockout
mice for the PKNs have not been published, yet and like for the
RSK isoforms it is currently unknown whether functional
redundancy exists between the isoforms.
Using physiological infection conditions, our present study
confirms an earlier report that YopM forms a complex with
members of the RSK and PKN kinase families. We found that
YopM induces long lasting activation of RSK even in the absence
of upstream ERK-signalling. In vivo and in vitro evidence is
provided that YopM interferes with dephosphorylation of RSK
most likely by shielding it from the action of phosphatases. Hence,
we can provide a novel mode of action of a bacterial effector
protein explaining how hyperphosphorylation and overactivation
of RSKfamily kinases is achieved.
Materials and Methods
Antibodies and plasmids
Antibodies. Anti-flag was from Sigma and used in the
dilution 1:3000, anti-myc clone 9E10 was from Cell Signaling
and used in the dilution 1:1000, anti-HA high affinity was from
Roche and used in the dilution 1:1000, anti-phospho-S380RSK
was from Cell signaling and used in the dilution 1:1000, anti-
phospho-S221RSK was from R&D systems and used in the
dilution 1:2000, anti-RSK1 was from Santa Cruz Bitotechnology
and used in the dilution 1:1000, anti-ERK1/2 was from Cell
Signaling and used in the dilution 1:1000, anti phospho-ERK1/2
was from Cell Signaling and used in the dilution 1:1000, anti-
YopM was a gift from Ju ¨rgen Heesemann and used in the dilution
1:3000. Anti-actin was from Millipore and used in a dilution of
1:1000. Secondary antibodies against rabbit-IgG, rat-IgG and
mouse-IgG were all from GE Healthcare and Horse radish
peroxidase conjugated. All used in a dilution of 1:10000.
Plasmids. The following expression plasmids have been
described previously: HA-tagged RSK1 [36](Addgene plasmid
13841), Flag-tagged PKN1 [37], Flag-tagged PKN2 [38], YopM
(nucleotide sequence corresponding to the Yersinia enterocolitica WA
Serotype O:8 YopM gene of the virulence plasmid pYV127/90;
gi: 28372983) in pACYC184 [39]. Clones for in vitro translation
have been obtained from ImaGenes GmbH (Berlin, Germany),
except PKN1 for which the above mentioned expression clone was
used: RSK1 (gi:15929012), RSK2 (gi:109730041), RSK3
(gi:27696716), RSK4 (gi:32450548), PKN2 (gi:30354737), PKN3
(gi:38565959). HA-tagged RSK2 was created by amplifying a
RSK2 fragment from gi:109730041 (see above, RSK2 in pCR-
BluntII-Topo) with AGGTACCGCTAGCCATGGCATACCC-
ATACGACGTCCCAGACTACATGCCGCTGGCGCAGCTG-
GCGGA and TCTACCAAGATATCACGTTCCA: This frag-
ment was digested with KpnI and EcoRV and cloned into the
similarly digested gi:109730041. From there the whole construct
was cut out with NheI and NotI and cloned into the similarly
digested vector pCI-neo. Myc-YopM was created by amplifying
YopM from YopM in pACYC184 mentioned above with the
primers Forward CTGACCATGGAATATGGTTTTGTTTGC-
AATGAA and Reverse GTCACTCGAGCTACTCAAAAACA-
TCATCTTCAAG. Subsequently, it was cloned via the restriction
sites NcoI and XhoI into the pCS2+MT vector. For bacterial
expression of Glutothione-S-transferase- (GST-) tagged YopM,
YopM was amplified from YopM in pACYC184 using the primers
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and Reverse GAAGCTTTCTACTCAAAAACATCATCTTCA-
AG and subsequently cloned into the pGEX-KG vector [40] via
the restriction sites BamHI and HindIII. YopM-CBP-SBP in
pACYC184 was created by amplification of a fragment of YopM
with the primers ATTGATCCATATGAATTTGCTCAT and
TTCTAGAGTACGCGGCCGCCTCAAAAACATCATCTTC-
AAG, digestion with NdeI/XbaI and ligation into YopM in
pACYC184 which had also been digested with NdeI and XbaI.
This resulted in a YopM without a stop codon and a 39-NotI-
restriction site. The tandem-affinity-tag containing the Calmodulin-
Binding-Peptide (CBP) [41] and the Streptavidin-Binding-Peptide
(SBP) [42,43] were derived from the commercially available
pNTAP-vector from the Interplay
TM Tandem Affinity Purifica-
tion system (Stratagene) via the following cloning steps. Stop codons
(oligo F: GATCCTAATTAATTAAG; oligo-R: GATCCTTAAT-
TAATTAG) were inserted into the BamHI site of pNTAP.
Afterwards, an XbaI-linker (New England Biolabs) was inserted
into the EcoRV site of pNTAP. The resulting pNTAP and the
YopM-pACYC184 construct without stopcodon and the additional
NotI site described above were then digested by NotI and XbaIa n d
the insert from pNTAP was ligated into the YopM-pACYC184
construct resulting in a YopM C-terminally tagged with the two
consecutive affinity tags CBP and SBP from the pNTAP vector.
Chemicals. MEK1/2-inhibitor (SL327; Z-& E-a-(Amino-((4-
aminophenyl)thio)methylene)-2-(trifluoromethyl)benzeneacetonitr-
ile) and HA1077 were all purchased from Calbiochem, rotenone,
2-deoxyglucose and Flag-sepharose were purchased from Sigma.
Cell culture, transfection, ATP-Depletion and infection
HEK293T (ATCC# CRL-11268) cells were grown on 100 mm
or 35 mm tissue culture dishes (Nunc) at 37uC and 5% CO2 in
DMEM with 10% FCS containing 100 IU/ml Penicillin and
100 mg/ml Streptomycin (all from Gibco). Transfection was
carried out at approximately 50% confluence using the Calcium
phosphate method following standard procedures. During serum
starvation conditions HEK293T cells were incubated in DMEM
as described above without FCS for 12 hours. For serum
starvation medium was exchanged 16–24 hours before harvesting
to serum-free DMEM with 100 IU/ml Penicillin and 100 mg/ml
Streptomycin. For MEK1/2 inhibition 48 hours after transfection
HEK293T cells were serum-starved and 16–24 hours later were
treated with 6 mM MEK-inhibitor (see above under Chemicals).
60 minutes later cells were harvested. For ATP-depletion of
HEK293T cells the medium was exchanged for PBS (Gibco)
containing 10 mM 2-deoxyglucose and 5 mM rotenone (both from
Sigma) [44]. J774A.1 (ATCC# TIB-67) cells were grown in
RPMI1640 supplemented with 10% FCS, 100 IU/ml Penicillin
and 100 mg/ml Streptomycin and additional 2 mmol Glutamine
(all from Gibco). Upon infection medium of J774A.1 cells were
changed to antibiotic free RPMI1640.
Yersinia strains and Infection – Yersinia enterocolitica strains used in
this study are deltaYopM, a derivative of the Yersinia enterocolitica
Serotype O:8 strain WA-314 harbouring the virulence plasmid
pYVO8 [45], in which the YopM gene had been replaced by a
kanamycin resistance cassette [10], the same deltaYopM strain
complemented with the DNA construct YopM-CBP-SBP in
pACYC184 (described under plasmids) (deltaYopM(pYopM-CBP-
SBP)), deltaYopM complemented with YopM in pACYC184 [39]
(deltaYopM(pYopM)), WA-C(pTTSS), the virulence plasmid
cured Yersinia enterocolitica strain WA-C [45] harbouring the
plasmid pTTSS encoding the TTSS secretion/translocation
apparatus of WA-314 but no Yop effector gene [39] and WA-
C(pTTSS) complemented with YopM in pACYC184 (WA-
C(pTTSS+pYopM)). For infection, Yersinia cultures were grown
overnight at 27uC and then diluted 1:20 in fresh Luria-Bertani
broth and grown for another 2 h at 37uC in order to induce
activation of the Yersinia type III secretion machinery and
expression of Yops. Bacteria were centrifuged and resuspended
in ice-cold PBS. J774A.1 cells were then infected by addition of
bacteria to the antibiotic free medium at a multiplicity-of-infection
of about 50:1. 90 min after infection of cells the bacteria were
killed by the addition of gentamicin (100 mg/ml). Cells were
harvested and lysed in phosphatase inhibition buffer (PBS, 25 mM
beta-glyerophosphate, 1 mM sodiumfluoride, 1 mM Orthovana-
date, 1x Complete protease inhibitor cocktail (Roche)) at the
indicated time points.
Tandem Affinity purification
Ten 100 mm culture dishes of J774A.1 cells (approximately
1610
8 cells) were infected with deltaYopM(pYopM-CBP-SBP) as
described above. 90 min after infection the cells were washed 3
times with PBS and were then harvested and lysed in 10 ml of the
lysis buffer supplied with the Interplay
TM Tandem Affinity
Purification kit (Stratagene) by three freeze-thaw rounds. The
following tandem affinity purification procedure was performed
according to the instructions of the manufacturer. Briefly, the
lysate was cleared by centrifugation and then incubated with
streptavidin sepharose for 2 hours at 4uC under constant rotation,
washed three times with the provided streptavidin binding buffer
and was then eluted with streptavidin elution buffer. This eluate
was then incubated with calmodulin sepharose for another 2 hours
at 4uC and subsequently washed again three times with
calmodulin binding buffer. The washed beads were boiled for
10 min in 2x SDS-loading buffer and loaded onto a SDS-PAGE.
Afterwards, the gel was Coomassie stained and the visible bands
cut out and analyzed by mass spectrometry.
Mass spectrometry
The proteins (bands cut out from Coomassie stained SDS gels)
werereduced with 10 mM dithiothreitol(DTT) at 56uC for 30 min,
the cysteine residues modified with iodacetamid (55 mM, ambient
temperature, 20 min in the dark) and the protein in-gel digested
withtrypsin(conditions:5 ng trypsin/ml (sequencing grade modified
trypsin, Promega, Madison, USA) in 50 mM NH4HCO3,3 7 uC,
16 h). After digestion the gel pieces were repeatedly extracted (50%
acetonitrile/5%formicacid), thecombined extractsdrieddown ina
vacuum concentrator and redissolved in 5% methanol/5% formic
acid. 0.5 ml of sample was mixed with an equal volume of matrix
solution (saturated solution of cyano-4-hydroxycinnamic acid
(HCCA) in 65% water/35% acetonitrile/0.1% trifluor acetic acid
(TFA)) and applied onto a MALDI target by the dried-droplet
method. Peptide mass fingerprint data were determined on a
MALDI-TOF mass spectrometer (REFLEX IV, Bruker Daltonics,
Bremen, Germany) in reflector mode. Database searches were done
with the Mascot search algorithm version 2.2 (Matrix Sciences,
London, UK) using the following parameter: mass tolerance:
50 ppm, one missed tryptic cleavage allowed, fixed modification:
carbamidomethyl cysteine, variable modification: monooxidized
methionine, database searched: NCBI nr 20100116, searches
limited to mus musculus.
Bacterial protein expression, purification and pull-down
assay
Bacterial protein expression and purification were done
essentially as described [46]. Briefly, the empty pGEX-KG or
YopM in pGEX-KG were transformed into BL21 E. coli. 20 ml
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under constant shaking at 37uC to an OD of about 0.6. Then
isopropyl thio-b-D-galctoside (IPTG) was added to a final
concentration of 1 mM and cultures were incubated for further
four hours. Bacteria were then harvested by centrifugation,
resuspended in PBS with 1x Complete protease inhibitor cocktail
(Roche) and lysed by ultrasonification. After pelleting the bacterial
debris by centrifugation, the supernatant was aliquoted and stored
at 280uC. Bacterial lysates were then used either for purification
or for pull-down assays. In order to purify GST or GST-YopM
bacterial lysates were poured onto a column loaded with 0.5 ml
Glutathion-sepharose resin (GE-Healthcare). After binding the
column was washed with 10 ml PBS +1% Triton-X100 and
subsequently with 10 ml PBS. Proteins were eluted from the
sepharose in 5 ml 100 mM NaCl, 50 mM Tris pH 7.5, 20 mM
Glutathion (Sigma) and 1x Complete protease inhibitor cocktail
(Roche). Protein amounts in the eluates were quantified by DC
protein assay (Biorad). GST-pull-down assays were essentially
done as described [47]. 50 mL of a 50% slurry Glutathion-
sepharose was loaded with either GST or GST-YopM. After
washing of the loaded sepharose and resuspension in binding
buffer (PBS, 1% NP40, 1x Complete protease inhibitor (Roche)),
5 mlo f[
35S]-methionine (Hartmann Analytic GmbH, Braunsch-
weig, Germany) labeled in vitro translated (TNT coupled
transcription/translation system from Promega GmbH, Mann-
heim) proteins were added. After overnight incubation, the
sepharose was washed eight times in binding buffer, boiled in 2x
SDS-loading buffer and loaded onto a SDS-PAGE. Bound
proteins were visualized by autoradiography.
Western blot analysis
Cellular lysates were prepared by three consecutive freeze/thaw
cycles in phosphatase inhibition buffer (PBS, 25 mM beta-
glyerophosphate, 1 mM sodiumflouride, 1 mM Orthovanadate,
1x Complete protease inhibitor cocktail (Roche)). Lysates were
then resolved in 10% SDS polyacrylamide gels and afterwards,
proteins were transferred to PVDF membranes by electroblotting.
Membranes were blocked in 5% milk powder in PBS +0.1%
Tween for 1 h and subsequently incubated with the indicated first
antibodies diluted in blocking solution overnight at 4uC. After
washing three times in PBS +0.1% Tween, membranes were
incubated in the appropriate second antibody for 2 h at room
temperature, washed three times as above and bands were
visualized by the ECL system (GE Healthcare). For the
quantification of Westernblots femtoLUCENT
TM PLUS-HRP
(G-Biosciences) was used as chemiluminescence reagent. Chemi-
luminescence was recorded with the LAS 4000 mini Luminescent
Image Analyzer (Fujifilm Corporation) and signals were analyzed
using the Multi Gauge V3.2 software.
Immunoprecipitation
HEK293T cells were co-transfected with the indicated plasmids.
Cells were lysed 48 hours after transfection in PBS +1% Triton X-
100 supplemented with Complete protease inhibitor cocktail by
three consecutive freeze/thaw cycles. After clearing of the lysate by
centrifugation lysates were incubated with 20 ml Flag-sepharose
(Sigma) overnight. Afterwards the sepharose was washed eight times
with1 ml lysis buffer and then resuspended in 2x SDS-buffer,boiled
and loaded onto SDS-PAGE. After western blotting, the membrane
was incubated with the indicated antibodies.
In vitro dephosphorylation assay
50 ng active RSK, ERK2 and MEK1 (Millipore) were
preincubated with 1 mg of bacterially expressed GST or GST-
YopM in lambda phosphatase buffer (New England Biolabs)
supplemented with Complete protease inhibitor cocktail (Roche)
in a total volume of 20 ml for 15 minutes on ice. Subsequently,
2000 units (0.5 ml) lambda phosphatase (New England Biolabs)
were added and the reactions were incubated for 5 min for p-
S380RSK and 60 min for p-S221RSK, ERK2 and MEK1 at
30uC under constant shaking. Reactions were stopped by adding
20 ml 2x SDS buffer and boiling for 10 min. 20 ml of each reaction
were then loaded onto a SDS-PAGE and analyzed by western
blotting.
Results
YopM interacts with all PKN and all RSK isoforms
A previous study identified PKN2 and RSK1 as interaction
partners of YopM [23]. In order to verify these interaction
partners under lifelike infection conditions and to potentially
discover novel ones, we translocated affinity tagged YopM into the
macrophage cell line J774A.1 via the TTSS of Yersinia. For this
purpose the coding region of the Yersinia enterocolitica Serotype O:8
strain WA-314 YopM gene was fused N-terminally to a Tandem-
affinity-Purification tag (TAP-tag), which consists of two separate
affinity tags, one calmodulin binding peptide (CBP) and one
streptavidin binding peptide (SBP), which can be specifically eluted
from their affinity matrices with EGTA and Biotin, respectively.
The fusion-construct was transformed into a Yersinia enterocolitica
O8 strain in which the YopM gene had been deleted, WA-
deltaYopM, resulting in the complemented strain WA-del-
taYopM(pYopM-CBP-SBP) (Fig. 1A). This complemented strain
was then used to infect J774A.1-cells. Lysates of the infected cells
were first bound to a Streptavidin-sepharose-matrix and subse-
quently eluted. This eluate was then adsorbed to a Calmodulin-
sepharose and eluted again. The eluate was separated by SDS-
PAGE and Coomassie stained. The visible bands were cut out and
analyzed by mass spectrometry (Fig. 1B). While no proteins were
precipitated when cells were infected with the uncomplemented
deltaYopM strain (not shown), several proteins were bound by
YopM-CBP-SBP. Two members of the RSK family, RSK1 and
RSK2, and two members of the PKN family, PKN1 and PKN2,
were identified. Thus, besides confirming the already described
interaction of YopM with RSK1 and PKN2, our screen recovered
RSK2 and PKN1 as novel binding partners, which are closely
related isoforms of RSK1 and PKN2. All proteins were identified
by peptide mass fingerprint analysis resulting in very low expect
values (Table 1). The interactions were also verified vice-versa.
Following infection YopM-SBP-CBP not only pulled down RSK1
and PKN1 but was also efficiently co-immunoprecipitated with
RSK1 and PKN1 (Fig. S1).
In order to further confirm the interaction of the identified
proteins with YopM GST-pull-down assays were performed.
Bacterially expressed GST or GST-YopM immobilized to
Glutathione-sepharose were separately incubated with in vitro
translated [
35S]-methionine labeled PKN1, PKN2, RSK1 or
RSK2. All labeled proteins bound to GST-YopM but not to GST
alone (Fig. 2A) indicating a direct interaction with YopM. Our
finding that YopM interacts with two isoforms of each kinase
family prompted us to investigate whether YopM also binds to the
other members of the RSK and PKN families. Indeed, in GST
pull-down assays we found binding of YopM to PKN3, RSK3 and
to RSK4 (Fig. 2B). These findings indicate that YopM interacts
with all known members of the RSK and PKN family of kinases.
It was shown that YopM assembles PKN2 and RSK1 into one
complex [23]. As we discovered that YopM interacts all with
known members of the RSK- and PKN families we sought to
Overactivation of RSK by YopM
PLoS ONE | www.plosone.org 4 October 2010 | Volume 5 | Issue 10 | e13165analyze whether these proteins are assembled in arbitrary
combinations or whether preferred combinations exists. Thus,
we analyzed interactions between the kinases shown to associate
with YopM in J774A.1 cells according to our tandem affinity
purification assay. First, we asked whether PKN1 can co-
immunoprecipitate both RSK1 and RSK2 in the presence of
YopM and whether the same is true for PKN2. As shown in
Figure 2C YopM can be robustly co-immunoprecipitated with
PKN1 and PKN2. Furthermore, RSK1 (left upper panel) and
RSK2 (right upper panel) could separately be co-immunoprecip-
itated with PKN1 in the presence but not in the absence of YopM.
The same results were obtained when co-immunoprecipitation
with PKN2 was assayed (left lower and right lower panel). These
experiments confirm the earlier finding that PKN isoforms
physiologically do not interact with RSK. Interaction occurs only
if YopM is present in the cell. Furthermore, there does not seem to
be a preference of one PKN isoform for a specific RSK isoform.
These results suggest that YopM forms complexes of RSK and
PKN subunits in an arbitrary combination.
YopM inhibits deactivation of RSK in the absence of ERK
signalling
YopM has been described to induce activation of RSK in kinase
assays, yet the underlying mechanism has not been further
investigated [23]. We determined in YopM- versus empty vector-
transfected serum-starved HEK293T cells the activation status of
RSK by analyzing phosphorylation at serine 380, which correlates
well with kinase activity [48], and phosphorylation at serine 221 in
the activation loop which is also critically important for kinase
activity [49,50]. We found significant activation of the MEK-
ERK-RSK pathway in our HEK293T cells as exemplified by
strong basal phosphorylation of ERK1/2 at threonine 202/
tyrosine 204 and RSK at serine 380 and serine 221 also under
serum starvation conditions (Figure 3). Though the phosphoryla-
tion status of ERK did not differ between YopM and empty vector
transfected cells, RSK was hyperphosphorylated at serine 380
when YopM was present. When MEK inhibitor was added to the
medium ERK1/2 and RSK serine 380 were rapidly dephosphor-
ylated in empty vector transfected cells. Quantification revealed
that phosphorylation of serine 380 of RSK was reduced by 60+/
214% in one hour in these cells (mean value and standard
deviation was calculated from 8 measurements from three
independent experiments). In contrast, RSK phosphorylation at
serine 380 in the YopM transfected cells declined much slower,
only 23+/213% in one hour, although ERK was as rapidly
dephosphorylated as in the empty vector transfected cells. Thus,
RSK remains phosphorylated at serine 380 in the presence of
YopM even when activating upstream signals from MEK-ERK
are inhibited. Phosphorylation at serine 221 was unaltered by the
Figure 1. Identification of YopM interacting proteins by
tandem-affinity-purification. (A) HEK293T cells were infected with
the indicated strains, lysed and extracts were subjected to western
blotting with anti-YopM antibody. (B) J774A.1 cells were infected with
deltaYopM(pYopM-CBP-SBP) and lysates were prepared 90 minutes
after infection. After tandem affinity purification the beads were boiled
and subjected to SDS-PAGE. Visible bands after Coomassie-staining
were excised and subsequently analyzed by mass spectrometry.
doi:10.1371/journal.pone.0013165.g001
Table 1. Peptides identified by peptide mass fingerprint analysis.
Protein Expect Identified peptides
PKN1 2.9e-9 LKEGAENLR; EGAENLRR; SLAPVELLLR; KLLLTAQQMLQDSK; LLLTAQQMLQDSK; KAVSEAQEK; LGELPADHPK; NLPETIPWSPPPSVGA;
SSLRGEAENATEVSTV; ELELAVFWR; LEDFLDNER; QMNIDVATWVR; SPLTLEDFK; SSGELFAIK; LDNLLLDTEGYVK; FLSAEAIGIMR;
SLGWDVLLAR; RLPPPFVPTLSGR; LPPPFVPTLSGR; DARPLTAAEQAAFR
PKN2 9.1e-10 SSVVIEELSLVASPTLSPR; FTLELDR; ELEISVYWR; LEDFLDNQR; APQMNINIATWGR; ATSVALPGWSPSDNR; AIPTVNHSGTFSPQTP;
LDFDLEPEPPPAPPP; VLDIPGQGSETVFNIE; SKSEYELSIPDSGRSCWGVGELD; SCWGVGELD; FQFSLQDFR; IFETVNSVR; FLSTEAISIMR;
VKPPFVPTIR
RSK1 1.1e-13 EISITHHVK; VLGQGSFGK; KVTRPDSGHLYAMK; DILADVNHPFVVK; LHYAFQTEGK; DLKPENILLDEEGHIK; LTDFGLSK;
LGMPQFLSTEAQSLLR; LGSGPDGAEEIKR; HIFYSTIDWNK; DSPGIPPSAGAHQLFR; GFSFVATGLMEDDGKP; TTQAPLHSVVQQLHGK;
RDPSEEIEILLR; YGQHPNIITLK; HVYLVTELMR; QKFFSER; TVEYLHSQGVVHR; DLKPSNILYVDESGNPECLRICDFGFAK;
FTLSGGNWNTVSETAK; MLHVDPHQR; QVLQHPWITQK; DKLPQSQLSHQDLQLVK
RSK2 1.4e-6 VVGVGVGVELALGGAAAAR; DILVEVNHPFIVK; DLKPENILLDEEGHIK; LGMPQFLSPEAQSLLR; LGAGPDGVEEIKRHSFFSTIDWNK;
DSPGIPPSANAHQLFR; RDPTEEIEILLR; TVEYLHAQGVVHR; NQSPVLEPVGR
doi:10.1371/journal.pone.0013165.t001
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35S]-methionine labeled in
vitro translated proteins. (B) Interactions between YopM and further RSK and PKN isoforms not recovered by Tandem affinity purification, RSK3, RSK4
and PKN3, were analyzed by pull-down assays as in (A). (C) HEK293T cells were transfected with the indicated plasmids and harvested after 48 hours.
Lysates were then incubated with 20 ml of Flag-sepharose and the precipitates and aliquots of the lysates before immunoprecipitation were analyzed
by western blotting with the indicated antibodies.
doi:10.1371/journal.pone.0013165.g002
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indicate a slower phosphorylation/dephosphorylation turnover at
this site. Thus, YopM induces hyperactivation of RSK without
altering ERK activity and inhibits deactivation of RSK in the
absence of upstream ERK signalling.
YopM inhibits dephosphorylation of RSK
In the absence of YopM ERK1/2 and RSK obviously become
rapidly and thoroughly dephosphorylated and thereby inactivated
when upstream MEK signalling was inhibited indicating tight
regulation of the MEK-ERK-RSK pathway by phosphatases. We
hypothesized that the sustained phosphorylation of RSK at serine
380 caused by YopM might result from impaired dephosphoryla-
tion, maybe through protection from phosphatases. To further
investigate this idea, we performed ATP-depletion assays. Due to
inhibition of glycolysis by 2-deoxyglucose and the respiratory chain
by rotenone as well as by exchanging the medium for glucose free
PBS intracellular ATP is consumed by the cell but not replenished
[44]. In vector transfected HEK293T cells, we observed a rapid
dephosphorylation of ERK1/2 and RSK at serine 380 after
induction of ATP-depletion conditions indicating again a rather fast
turnover at these phosphorylation sites (Figure 4, left panel). Serine
380 of RSK was completely dephosphorylated after 5–10 minutes.
In contrast, phosphorylation of serine 380 in YopM transfected cells
remained stable for at least 30 minutes with only minor
dephosphorylation (Figure 4, right panel). In parallel ERK1/2
was dephosphorylated comparably as in vector transfected cells,
indicating that the YopM effect on dephosphorylation inhibition is
specific forRSKandindependent from upstream signalling.Asseen
before, phosphorylation declined very slowly if at all at serine 221
under these conditions, consistent with a slow dephosphorylation
kinetic. Addition of HA1077, an inhibitor of PKN, prior to ATP-
depletion did not reverse the effects of YopM (data not shown).
These results strongly suggest that YopM protects phosphorylated
RSK from the dephosphorylation by phosphateses.
In order to further investigate whether YopM directly protects
RSK from dephosphorylation we performed in vitro dephosphor-
ylation assays with purified defined components. Therefore we
incubated purified commercially available active RSK1 (pre-
phosphorylated by active ERK1/2 and PDK1) with lambda
phosphatase in the presence of bacterially expressed and purified
GST or GST-YopM. RSK1 was readily dephosphorylated by
lambda phosphatase on serine 380 and serine 221 when GST was
added to the reaction mix (Fig. 5A). In sharp contrast, when GST-
YopM was added dephosphorylation of serine 380 and serine 221
by lambda phosphatase was effectively inhibited. This effect of
YopM was specific for RSK as neither ERK2 nor MEK1 were
protected by YopM from dephosphorylation by lambda phospha-
tase. We also tested whether RSK2, RSK3 and RSK4 are
protected from dephosphorylation by YopM by analysing
phosphorylation at serine 380 in RSK2 and RSK4 and at serine
221 in RSK3. All RSK isoforms were efficiently dephosphorylated
Figure 3. YopM induces RSK activation in the absence of ERK
signalling. HEK293T were transfected with the indicated plasmids.
48 hours after transfection cells were serum-starved and 16–24 hours
later were treated with 6 mM MEK-inhibitor. 60 minutes later cells were
lysed and the lysates subjected to western blotting with the indicated
antibodies.
doi:10.1371/journal.pone.0013165.g003
Figure 4. YopM protects RSK from dephosphorylation during ATP-depletion. 48 hours after transfection of HEK293T with the indicated
plasmids, the medium of the cells was exchanged with PBS supplemented with rotenone and 2-deoxyglucose. Cells were then harvested in 5 minute
intervals and flash frozen. Westernblots of the lysates were then analyzed with the indicated antibodies.
doi:10.1371/journal.pone.0013165.g004
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clearly inhibited this process (Fig. 5B). These findings further
corroborate the conclusions from the ATP-depletion and the
MEK inhibition experiments, that YopM inhibits dephosphory-
lation of activated RSK isoforms. These results also prompted us
to ask whether YopM might specifically interact with phosphor-
ylated RSK. We performed GST-pull-down assays with active
RSK1 (see above) which was either left untreated or was
pretreated with lambda phosphatase for 90 minutes, the latter
resulting in complete dephosphorylation. We could clearly show
that YopM interacts with both phosphorylated and unpho-
sphorylated RSK1 (Fig. 5C). Thus interaction with YopM is
independent from the phosphorylation status of RSK.
Translocation of YopM during infection inhibits RSK
dephosphorylation after initial activation
Lastly, we analyzed whether we could also find an influence of
YopM on the RSK phosphorylation status in J774A.1 cells during
infection. We used four different Yersinia strains for these
experiments. Two strains express modules constituting a functional
type-three-secretion system, without (WA-C(pTTSS)) or with
YopM complementation (WA-C(pTTSS+pYopM)). The other
two strains were the YopM-deleted strain WA-deltaYopM and
WA-deltaYopM complemented with YopM (WA-deltaYopM
(pYopM)). Using backgrounds which either express other Yops
(WA-deltaYopM) or not express any other Yops (WA-C(pTTSS)
served to investigate whether other Yops influence the effects of
YopM. Furthermore, the two different backgrounds WA-
C(pTTSS) and WA-deltaYopM were used to overexpress YopM
as both WA-C(pTTSS+pYopM) and WA-deltaYopM(pYopM)
express YopM from a plasmid. This resulted in an about five-fold
overexpression of YopM compared to wildtype strain WA-P as
determined by westernblot quantification of lysates from infected
cells (also demonstrated in Figure S2). This enabled us to observe
YopM mediated effects on RSK phosphorylation more clearly
than with a wildtype strain.
In contrast to the HEK293T cells, basal serine 221 and serine
380 phosphorylation levels of RSK in J774A.1 cells were low
under resting conditions (Fig. 6). Upon infection with each of the
four Yersinia strains RSK phosphorylation at serines 380 and 221
rapidly increased with a maximum at about 30–60 minutes after
infection. In cells infected with the strains WA-C(pTTSS) (Fig. 6,
left upper panel) and WA-deltaYopM (Fig. 6, left lower panel)
serine 380 and serine 221 phosphorylation declined progressively
after 60 minutes. The decrease of phosphorylation of RSK was
parallel to the decrease of ERK-phosphorylation without detect-
able delay confirming tight coupling of ERK and RSK activation.
In contrast, in J774A.1 cells infected with Yersinia strain WA-
C(pTTSS+pYopM) (Fig. 6, right upper panel) and WA-del-
taYopM(pYopM) (Fig. 6, right lower panel) phosphorylation of
RSK remained at a constant level indicating impaired dephos-
phorylation and deactivation of RSK. At the same time decrease
of ERK phosphorylation proceeded with the same kinetics as in
cells infected with YopM-negative Yersinia strains indicating a
YopM-dependent uncoupling of RSK activation/phosphorylation
Figure 5. YopM specifically protects RSK from dephosphory-
lation during in vitro dephosphorylation assays. (A) 50 ng active
RSK1 and 1 mg GST or 1 mg GST-YopM were preincubated in lambda-
phosphatase buffer for 15 minutes on ice. Then 1 ml of lambda
phosphatase was added and the reaction was transferred to 30uC under
gentle constant shaking. The reaction was stopped by addition of 2x
SDS buffer and boiling. After western blotting analysis was carried out
with the antibodies indicated. (B) As in (A) except that RSK2, RSK3 and
RSK4 were used in the reaction. (C) YopM interacts with both
phosphorylated and unphosphorylated RSK1. 500 ng active RSK was
pretreated for 90 minutes with lambda phosphatase, while 500 ng was
left untreated. 250 ng of the dephosphorylated or the active RSK1 was
then incubated with GST or GST-YopM bound to Glutathione-sepharose
and processed as described under pull-down in the Experimental
Procedures section. After washing the beads were boiled in 2x SDS
buffer and subjected to western blotting with the antibodies stated.
doi:10.1371/journal.pone.0013165.g005
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infection conditions YopM induces protracted RSK activation/
phosphorylation independent of ERK signalling. In general we did
not observe major differences between cells infected with WA-
deltaYopM or WA-C(pTTSS) backgrounds indicating that other
Yops do not influence YopM effects on RSK phosphorylation.
Noteworthy, under our experimental condition we did not observe
significant inhibition of ERK1/2 by YopP, which is present in the
WA-deltaYopM but not in the WA-C(pTTSS) background.
Competition for translocation due to overexpression of YopM
may be one explanation, though we still observed YopP-induced
apoptosis at later time points in the J774A.1 cells indicating YopP
translocation at effective levels. Also, different levels of phagocy-
tosis resistance obviously do not result in differences between the
WA-deltaYopM or WA-C(pTTSS) backgrounds, probably due to
the rapidity of type three secretion mediated effector injection.
Taken together, we conclude from the experiments described
above that YopM protects RSK from dephosphorylation leading
to its sustained activation.
Discussion
All intracellular Yops exert their effects on the cell by interacting
with cellular proteins and modifying their activity [5]. The aim of
Figure 6. YopM delivered during infection induces protracted activation of endogenous RSK in J774A.1 cells. J774A.1 cell were
infected with WA-C(pTTSS) (left upper panel) or with WA-C(pTTSS+pYopM) (right upper panel) or with WA-deltaYopM (left lower panel) or with WA-
deltaYopM(pYopM) (right lower panel) and harvested at the indicated time points. Bacteria were killed by the addition of gentamicin after 90
minutes. Cellular lysates were then subjected to western blotting and probed with the indicated antibodies.
doi:10.1371/journal.pone.0013165.g006
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under conditions which match the physiological situation during
infection as closely as possible. Therefore, we tagged YopM C-
terminally with two affinity tags to enable two consecutive affinity
purification steps. This allows purification of larger complexes as
no harsh elution conditions have to be employed and results in low
background contamination [51]. Furthermore, our approach
allows purification of proteins which bind to YopM during
infection, as in our experiments YopM is translocated via the
TTSS into the cell. By this, we identified four kinases, RSK1 and 2
and PKN1 and 2, as binding partners of YopM. Two of the
proteins, RSK1 and PKN2, have previously been described as
interacting partners of YopM [23]. Thus, our study identifies
additional YopM-interacting proteins and confirms previous
findings. Therefore, RSK and PKN family members are likely
to be major host cell mediators of YopM action. This is in line with
two very recent reports, which find reduced virulence of Yersinia
strains deficient for binding to RSK1 [52,53]. Several factors may
contribute that we recovered more interaction partners than
previous studies [23,52,53]. Beside methodological differences (use
of different cell lines, mode of YopM delivery, method of
purification) there is considerable variability between different
YopM proteins from different species and serogroups. While
previous investigations used YopM proteins with rather low LRR
numbers of 13–15 units, our YopM harbours 20 LRRs.
Furthermore, YopM proteins differ in their composition of
different LRRs, which are mostly 20 amino acids but some also
21 and 22 amino acids long with our YopM having only one 22
amino acid LRR (LRR 4). This may give rise to divergent binding
sites in particular for PKN members, as PKN2 has been found to
interact with an internal region of YopM comprising LRR 6–15
[53]. Moreover, although the C-terminal 6 amino acids of YopM
required for RSK1 binding are highly conserved other regions of
the YopM protein might contribute to the RSK binding
specificity. Thus, it currently remains to be determined whether
all YopM proteins are able to bind several members of the RSK
and PKN families.
The finding that YopM interacts with all members of the RSK
and the PKN family raises the question whether YopM exploits
the physiological functions of these kinases or whether these
kinases are hijacked and directed towards novel functional
contexts. With the exception of Rsk2, knockout mice have not
been published for RSK or PKN family members, thus no definite
statement can be made concerning redundancy, but some form of
specificity for these kinases seems very likely. Thus, interaction of
YopM with several isoforms may suggest, that no specific function
of RSK may be targeted. Furthermore, up to now we did not find
alterations in the phosphorylation status of diverse known
endogenous targets of RSK (data not shown). PKN targets have
not yet been investigated by us. Previous work suggested that
PKN2 is not directly activated by YopM but indirectly by the
overactivated RSK1 [23]. Different mechanisms are conceivable.
One may be that PKN is directly phosphorylated by RSK.
Another possibility might be activation by some steric mechanism
as we were not yet able to detect hyperphosphorylation of PKN in
YopM transfected cells (data not shown). It will be important to
dissect this process in more detail in future studies. Modulation of
RSK activity by YopM may have different consequences:
Sustained activation of RSK by YopM may result in sustained
phosphorylation of a specific subset of endogenous RSK targets,
which we and others could not identify so far. Alternatively,
activation of RSK may serve the only purpose of activating the
PKN subunits of the YopM complex which subsequently
phosphorylate physiological substrates. Lastly, activation of RSK
and/or PKN may result in the phosphorylation of unphysiological
substrates.
Interaction of YopM with RSK1 has been shown to activate
RSK1 as analyzed by kinase assays [23]. This study uncovers the
underlying molecular events resulting in sustained RSK activation.
We find that YopM protects all RSK isoforms from being
dephosphorylated in vitro and in vivo. It is currently not exactly
known, which phosphatases are involved in the dephosphorylation
of RSK, but the rapidity of dephosphorylation when upstream
ERK signalling is interrupted suggests a tightly regulated system.
Only two phosphatases, PP2Cdelta [54] and PP2A [55] have been
described to interact with RSK. We were not able to block
dephosphorylation of RSK under ATP-depletion conditions by
addition of 50 nM okadaic acid (data not shown), which is an
effective inhibitor of both PP2A and PP1. In our opinion this
argues against a major role in vivo for PP2A in dephosphorylation
of RSK. Members of PP2C family of phosphatases are notoriously
unresponsive to commercially available phosphatase inhibitors
[56], which may explain the insensitivity of the dephosphorylation
to okadaic acid. Whether several PP2C members are involved in
the regulation of RSK will have to be determined. The exact
dynamics of phosphorylation and dephosphorylation of RSK as
well as the identification of the factors involved will be an
important area of research in the future.
It is currently unclear how yersiniae may benefit from sustained
activation of RSK during infection. As already discussed above,
activation of RSK may only serve the subsequent activation of
PKN as we and others were so far unsuccessful in identifying
changes in the phosphorylation status of some of the endogenous
substrates of RSK ([23] and data not shown). RSK activation by
YopM may be confined to the microenvironment of the YopM
complex. Yet, although RSK has not been found to play a role
during bacterial infections, there are a number of studies reporting
virally induced pathologically sustained RSK activation during
viral infection and replication [57,58,59]. These studies found
sustained RSK activity to be important for replication of a broad
range of different unrelated viruses like HIV, KSHV and vaccinia
virus. Most importantly, the viral factor ORF45 from KSHV was
identified to induce sustained RSK activation by a mechanism
very similar to that of YopM [60]. ORF45 directly binds to RSK
and obviously physically shields ERK and RSK from dephos-
phorylation which results in constant RSK activation. In CMV
infection impaired dephosphorylation of ERK and p38 has been
implicated in efficient viral gene expression [61,62]. Thus,
activation of ERK-RSK may be a common and potentially
important incident during infection. However, none of the studies
identified the targets downstream of RSK which mediate the
effects of sustained activation or define the cellular events which
are induced. We can currently not unambiguously demonstrate
that overactivation of RSK is the critical molecular event
responsible for YopM-conferred pathogenicity. Yet we believe
on basis of our and the recent results of others [52,53] that this is
highly likely. We did not observe any other YopM-mediated on
the kinases like inhibition, degradation or subcellular mislocaliza-
tion (data not shown).
To summarize, in accordance with previous findings we
identified the RSK and PKN families of kinases as the intracellular
mediators of YopM effects. Moreover, we can clarify the
mechanism how interaction with YopM results in over-activation
of RSK with YopM shielding RSK from the action of
phosphatases resulting in sustained activating phosphorylation.
Protection of interacting proteins from dephosphorylation is a
novel function of a bacterial effector, which may apply also for
other leucine-rich-repeat containing proteins from other bacterial
Overactivation of RSK by YopM
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from Shigella [64]. Future studies will also have to address the
physiological functions of RSK and PKN in the immune defense
of the host during infection.
Supporting Information
Figure S1 J774A.1 cells were left uninfected (lane 1 left and right
panel) or were infected with deltaYopM(pYopM-CBP-SBP) (lanes
2–4 left and right panel)and lysates were prepared 90 minutes after
infection. Lysates were then incubated with 20 ml of Streptavidine-
sepharose (lanes 1 and 2 left and right panel) or Protein A/G
sepharose (lanes 3 and 4 left and right panel) and the precipitates
and aliquots of the lysates before immunoprecipitation were
analyzed by western blotting with the indicated antibodies.
Found at: doi:10.1371/journal.pone.0013165.s001 (0.57 MB
PDF)
Figure S2 Analysis of YopM quantities translocated into J774.1
cells by different Yersinia strains. J774.1 cell were infected with
WA-P, WA-deltaYopM, WA-deltaYopM(pYopM), WA-C(pTTSS)
and WA-C(pTTSS+YopM) and harvested after 90 min. Cellular
lysates were then subjected to western blotting and probed with the
indicated antibodies.
Found at: doi:10.1371/journal.pone.0013165.s002 (0.35 MB
PDF)
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